Viridian Therapeutics, Inc. (VRDN)
| Market Cap | 127.71M |
| Revenue (ttm) | 1.67M |
| Net Income (ttm) | -121.13M |
| Shares Out | 6.34M |
| EPS (ttm) | -31.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $17.53 |
| Previous Close | $17.36 |
| Change ($) | 0.17 |
| Change (%) | 0.98% |
| Day's Open | 17.68 |
| Day's Range | 17.30 - 17.86 |
| Day's Volume | 5,476 |
| 52-Week Range | 7.08 - 25.67 |
BOULDER, Colo., May 06, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underse...
BOULDER, Colo., March 25, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but under...
Viridian Therapeutics (NASDAQ:VRDN) releases its next round of earnings this Thursday, March 25. Here is Benzinga's essential guide to Viridian Therapeutics's Q4 earnings report.
Viridian Therapeutics, Inc. (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOULDER, Colo., March 09, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but under...
Viridian Therapeutics, Inc. (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOULDER, Colo., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a development-stage biopharmaceutical company, today announced that Jonathan Violin, Ph.D., President and Ch...
BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“V...
About VRDN
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in... [Read more...]
| Industry Biotechnology | Founded 2006 |
| CEO William Marshall | Employees 26 |
| Stock Exchange NASDAQ | Ticker Symbol VRDN |
Financial Performance
In 2020, VRDN's revenue was $1.05 million, a decrease of -76.46% compared to the previous year's $4.46 million. Losses were -$110.72 million, 164.4% more than in 2019.